Medical News

RSS

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria.

12 Aug 2014

NGS issues positive coverage decision for PTNS to manage symptoms of OAB

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for the proprietary Urgent PC device was effective August 10, 2014.

12 Aug 2014

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Valeant receives request for additional information from FTC under Hart-Scott-Rodino

Valeant Pharmaceuticals International, Inc. announced that the Company has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Valeant's proposed acquisition of Allergan, Inc.

12 Aug 2014

HRIC selects Softheon MC2 to integrate plan offerings for individuals and SHOP plans to FFM

Softheon, Inc., a proven leader in health insurance marketplace integration and business operation, announced today that Health Republic Insurance Company has chosen the Marketplace Connector Cloud (MC2) as their software platform that will integrate and transition its comprehensive plan offerings for individuals and SHOP plans, both on and off Exchange, to the Federally Facilitated Marketplace.

12 Aug 2014

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules.

12 Aug 2014

Fred's announces multi-year agreement for Cardinal Health to be new primary supplier

Fred's Inc., a leading provider of pharmacy services in the southeast and Cardinal Health, Inc., one of the nation's largest healthcare services companies, today announced a multi-year agreement for Cardinal Health to be the new primary supplier of branded and generic pharmaceutical products to all of Fred's more than 360 in-store pharmacies and EIRIS Health Services in the United States.

12 Aug 2014

BIOREM announces 4 new orders totalling $1.5 million

BIOREM Inc. today announced four new orders totalling $1.5 million. The orders include a biogas conditioning system and an odour control system in North America, as well as an industrial VOC/odour abatement system in Asia and a small odour control system in the Middle East.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

Australia introducing breakthrough cerebral palsy treatment

"If Id had a stroke, I wouldn't be happy waiting two years for a diagnosis and treatment, by which time the damage would have become permanent" says Professor Nadia Badawi, Macquarie Group Foundation Chair of cerebral palsy and Head of Research with Cerebral Palsy Alliance "Well that's what we accept with children with cerebral palsy when early intervention in infancy could re-shape their brains, for example using what's called a motor learning approach, where we train the brain to learn new movements."

11 Aug 2014

Schizophrenia-linked genetic variations and the developing brain: an interview with Prof. Guo-li Ming

How much is currently known about what happens in the developing brain that puts people at risk of schizophrenia?

11 Aug 2014

Nigral neuronal loss and α-synuclein pathology scrutinised in PD

The severity of neurodegeneration and local burden of α-synuclein are closely coupled during disease progression in Parkinson’s disease, a post-mortem study has found.

11 Aug 2014

In vivo dopaminergic imaging strongly correlates with brain pathology

Striatal dopamine transporter binding, assessed using single-photon emission computed tomography, is strongly correlated with substantia nigra cell counts assessed at postmortem, say the authors of a study.

11 Aug 2014

$Sacral magnetic stimulation effective in refractory stress incontinence$